CWP
BLRX

Concord Wealth Partners’s BioLineRX BLRX Stock Holding History

Concord Wealth Partners’s Portfolio BLRX Stock Details BLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-5
Closed -$1K – 920
2021
Q2 		$1K Sell
5
-20
-80% -$2.35K ﹤0.01% 948
2021
Q1 		$3K Buy
+25
New +$3.01K ﹤0.01% 746

Other funds holding BLRX

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
PHP
Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
PAM
PVG Asset Management Golden, Colorado $173M AUM 64.51% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $374B AUM 17.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
IP
Intellectus Partners San Francisco, California $490M AUM 35.11% 1-Year Est. Return

Concord Wealth Partners's BLRX Position: Q3 2021 in Review

Concord Wealth Partners sold out of BioLineRX (BLRX) in Q3 2021, closing a stake of 5 shares — an estimated $1K sold.

Concord Wealth Partners first reported a position in BLRX in Q1 2021 and held it in 2 quarters. The position peaked at $3K in Q1 2021. 29 funds tracked by Wall St. Rank hold BLRX as of Q3 2021.

  • Concord Wealth Partners reported no remaining BioLineRX position as of Q3 2021 after selling out during the quarter.
  • Concord Wealth Partners sold 5 BioLineRX shares in Q3 2021, an estimated $1K.
  • Concord Wealth Partners first reported a position in BioLineRX in Q1 2021 and held it in 2 quarters.
  • Concord Wealth Partners's BioLineRX position peaked at $3K in Q1 2021.
  • 29 funds tracked by Wall St. Rank held BioLineRX as of Q3 2021.

Based on Concord Wealth Partners's 13F filing for Q3 2021, filed 9 Nov 2021.